At the news
? NEUTRALIMPACT 3/10 DEFA14A filed Apr 24, 2026 at 16:08 ET
FATE THERAPEUTICS INC filed a definitive proxy statement for its 2026 annual shareholder meeting, proposing the election of three Class I directors, ratification of auditors, advisory approval of executive compensation, and an increase in shares available under its stock option plan.
- Annual shareholder meeting scheduled for June 12, 2026
- Proposing election of three Class I directors: Robert S. Epstein, Karin Jooss, and Laura J. Hamill
- Proposing to increase shares available under the 2022 Stock Option and Incentive Plan
- Proposing ratification of Ernst & Young LLP as independent auditors
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access